Ultragenyx Pharmaceutical Aktie
35,80
EUR
-0,80
EUR
-2,19
%
38,85
USD
-0,86
USD
-2,17
%
Werbung
Ultragenyx Pharmaceutical Aktie Analyse
11.05.18 | Ultragenyx Pharmaceutical overweight | Barclays Capital | |
21.02.18 | Ultragenyx Pharmaceutical Buy | Stifel, Nicolaus & Co., Inc. | |
05.12.17 | Ultragenyx Pharmaceutical Equal weight | Barclays Capital | |
14.09.17 | Ultragenyx Pharmaceutical Outperform | Wedbush Morgan Securities Inc. | |
08.08.17 | Ultragenyx Pharmaceutical Neutral | H.C. Wainwright & Co. | |
19.04.17 | Ultragenyx Pharmaceutical Neutral | Wedbush Morgan Securities Inc. | |
19.04.17 | Ultragenyx Pharmaceutical Neutral | H.C. Wainwright & Co. |
Werbung
Werbung